Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial

BACKGROUND: Combinations of avelumab [anti-programmed death-ligand 1 (anti-PD-L1)] or talazoparib [poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor] with binimetinib (MEK inhibitor) were expected to result in additive or synergistic antitumor activity relative to each drug administered...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodon Ahnert, J., Tan, D.S.-W., Garrido-Laguna, I., Harb, W., Bessudo, A., Beck, J.T., Rottey, S., Bahary, N., Kotecki, N., Zhu, Z., Deng, S., Kowalski, K., Wei, C., Pathan, N., Laliberte, R.J., Messersmith, W.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515283/
https://www.ncbi.nlm.nih.gov/pubmed/37379764
http://dx.doi.org/10.1016/j.esmoop.2023.101584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515283/
https://www.ncbi.nlm.nih.gov/pubmed/37379764
http://dx.doi.org/10.1016/j.esmoop.2023.101584

Ejemplares similares